阿哌沙班用于预防隐源性卒中伴心房病变患者卒中复发:ARCADIA随机临床试验
ARCADIA多中心双盲3期随机试验纳入1015例隐源性卒中伴心房病变患者,比较阿哌沙班与阿司匹林二级预防效果。平均随访1.8年,因无效提前终止。阿哌沙班组与阿司匹林组复发性卒中发生例数均为40例(年化率均为4.4%),HR 1.00(95%CI 0.64-1.55)。结论:阿哌沙班较阿司匹林未显著降低卒中复发风险。
要点
- 隐源性卒中伴心房病变患者中,阿哌沙班较阿司匹林未显著降低卒中复发风险。
- 复发性卒中:阿哌沙班组40例(年化率4.4%)vs 阿司匹林组40例(年化率4.4%),HR 1.00(95%CI 0.64-1.55)。
- 症状性颅内出血:阿哌沙班组0例 vs 阿司匹林组7例(年化率1.1%)。
核心结论
- 在隐源性卒中伴心房病变且无心房颤动的患者中,阿哌沙班较阿司匹林未显著降低复发性卒中风险。
研究设计与样本
- 多中心、双盲、3期随机临床试验,纳入1015例隐源性卒中伴心房病变患者,随机分配至阿哌沙班5mg或2.5mg每日两次组(n=507)或阿司匹林81mg每日一次组(n=508)。
- 心房病变定义为心电图V1导联P波终末电势大于5000μV×ms、血清N末端B型利钠肽原水平大于250pg/mL或超声心动图左心房直径指数≥3cm/m2。
- 入组及随访时间为2018年2月1日至2023年2月28日,在National Institutes of Health StrokeNet和Canadian Stroke Consortium的185个中心进行。
主要发现
- 平均随访1.8年,目标样本1100例中入组1015例后,经计划中期分析因无效而终止试验。
- 复发性卒中发生于阿哌沙班组40例(年化率4.4%)和阿司匹林组40例(年化率4.4%)(HR 1.00,95%CI 0.64-1.55)。
- 症状性颅内出血发生于阿哌沙班组0例和阿司匹林组7例(年化率1.1%)。
- 其他大出血发生于阿哌沙班组5例(年化率0.7%)和阿司匹林组5例(年化率0.8%)(HR 1.02,95%CI 0.29-3.52)。
临床怎么用
- 在隐源性卒中伴心房病变且无心房颤动的患者中,阿哌沙班较阿司匹林未显著降低复发性卒中风险。
局限性
- 目标样本1100例中仅入组1015例,试验经计划中期分析因无效而终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atrial cardiopathy is associated with stroke in the absence of clinically apparent atrial fibrillation. It is unknown whether anticoagulation, which has proven benefit in atrial fibrillation, prevents stroke in patients with atrial cardiopathy and no atrial fibrillation. OBJECTIVE: To compare anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, phase 3 randomized clinical trial of 1015 participants with cryptogenic stroke and evidence of atrial cardiopathy, defined as P-wave terminal force greater than 5000 μV × ms in electrocardiogram lead V1, serum N-terminal pro-B-type natriuretic peptide level greater than 250 pg/mL, or left atrial diameter index of 3 cm/m2 or greater on echocardiogram. Participants had no evidence of atrial fibrillation at the time of randomization. Enrollment and follow-up occurred from February 1, 2018, through February 28, 2023, at 185 sites in the National Institutes of Health StrokeNet and the Canadian Stroke Consortium. INTERVENTIONS: Apixaban, 5 mg or 2.5 mg, twice daily (n = 507) vs aspirin, 81 mg, once daily (n = 508). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome in a time-to-event analysis was recurrent stroke. All participants, including those diagnosed with atrial fibrillation after randomization, were analyzed according to the groups to which they were randomized. The primary safety outcomes were symptomatic intracranial hemorrhage and other major hemorrhage. RESULTS: With 1015 of the target 1100 participants enrolled and mean follow-up of 1.8 years, the trial was stopped for futility after a planned interim analysis. The mean (SD) age of participants was 68.0 (11.0) years, 54.3% were female, and 87.5% completed the full duration of follow-up. Recurrent stroke occurred in 40 patients in the apixaban group (annualized rate, 4.4%) and 40 patients in the aspirin group (annualized rate, 4.4%) (hazard ratio, 1.00 [95% CI, 0.64-1.55]). Symptomatic intracranial hemorrhage occurred in 0 patients taking apixaban and 7 patients taking aspirin (annualized rate, 1.1%). Other major hemorrhages occurred in 5 patients taking apixaban (annualized rate, 0.7%) and 5 patients taking aspirin (annualized rate, 0.8%) (hazard ratio, 1.02 [95% CI, 0.29-3.52]). CONCLUSIONS AND RELEVANCE: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03192215.
引用
- Kamel H, Longstreth WT, Tirschwell DL, et al. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. JAMA. 2024. PMID: 38324415. doi:10.1001/jama.2023.27188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。